Share on StockTwits

Sagent Pharmaceuticals (NASDAQ:SGNT) Director Robert J. Flanagan sold 16,000 shares of Sagent Pharmaceuticals stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $24.39, for a total transaction of $390,240.00. Following the completion of the sale, the director now directly owns 6,996 shares of the company’s stock, valued at approximately $170,632. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Sagent Pharmaceuticals (NASDAQ:SGNT) traded up 3.61% on Wednesday, hitting $25.25. The stock had a trading volume of 112,204 shares. Sagent Pharmaceuticals has a 52-week low of $17.49 and a 52-week high of $27.57. The stock has a 50-day moving average of $25.66 and a 200-day moving average of $22.71. The company has a market cap of $805.4 million and a P/E ratio of 53.56.

Sagent Pharmaceuticals (NASDAQ:SGNT) last announced its earnings results on Wednesday, July 30th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.01) by $0.10. The company had revenue of $69.20 million for the quarter, compared to the consensus estimate of $67.14 million. The company’s quarterly revenue was up 16.1% on a year-over-year basis. Analysts expect that Sagent Pharmaceuticals will post $0.26 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Sagent Pharmaceuticals from $20.00 to $27.00 in a research note on Thursday, July 31st. They now have a “sector perform” rating on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Sagent Pharmaceuticals from $24.00 to $27.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Sagent Pharmaceuticals from $23.00 to $25.00 in a research note on Thursday, July 31st. They now have a “hold” rating on the stock. Six investment analysts have rated the stock with a hold rating, Sagent Pharmaceuticals presently has an average rating of “Hold” and an average price target of $26.67.

Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.